Epidarex

Epidarex Capital – Catalyzing innovation in health science and technology

Apellis Pharmaceuticals Announces Pricing of Offering of Common Stock

CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the pricing of its underwritten public offering of 5,500,000 shares of…

Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab

Interim data shows broad hematologic correction including improved hemoglobin levels and reduction in LDH CRESTWOOD, KY. and WALTHAM, MA., April 16, 2018 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of…

Prof Dorien Peters Joins Mironid’s SAB

March 26, 2018 – Mironid is delighted to announce the appointment of Prof Dorien Peters to our Scientific Advisory Board Prof. Dr. Dorien Peters is a molecular geneticist and cellular biologist at the Leiden University Medical Center in the Netherlands. Her research aims to obtain…